The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
Relapse after HSCT 2021 | Management of relapse after CAR-T in patients with B-cell lymphoma
Peter Dreger
• 5 Oct 2021
Peter Dreger, MD, Heidelberg University Hospital, Heidelberg, Germany, describes the management of patients with B-cell lymphomas relapsing following treatment with CD19-targeted chimeric antigen receptor (CAR) T-cells, commenting on the role of allogeneic hematopoietic stem cell transplantation. This interview took place at the 2021 Relapse After HSCT² Workshop in New York, NY.
